Sickle Cell Gene Therapy Reimbursement: Will Experience Matter? And Which Kind?
• By Michael McCaughan
Generate a summary of this article
Listen to this article
The tandem launches of two gene therapies for sickle cell disease will likely be critical to determining whether and how US reimbursement policies can shape commercial success for hugely expensive, one-time treatments. Bluebird is the smaller, less-experienced company up against Vertex – but argues it has more relevant experience.
Simultaneous approvals are putting a spotlight on gene therapy reimbursement. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
The tandem launches of the first gene therapies to treat sickle cell disease will be an important test of the US reimbursement system for one-time gene therapies.
In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.
Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.
Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.